New disease-modifying treatment for Alzheimer’s Disease (Lecanemab) Enters Canada and Signals an Expanded Role for Radiology in patient management
Health Canada recently approved a new disease-modifying therapy (DMT) for the treatment of patients with early Alzheimer’s Disease (AD). This marks an exciting turning point in AD care, with Canada joining other countries in adopting this innovative treatment to fight AD. As the first DMTs enter Canadian clinical practice, radiologists will play a critical role […]









